| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FRZB |
| Uniprot No | Q92765 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-325aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSAACEPVRIPLCKSLPWNMTKMPNHLHH STQANAILAIEQFEGLLGTHCSPDLLFFLCAMYAPICTIDFQHEPIKPCK SVCERARQGCEPILIKYRHSWPENLACEELPVYDRGVCISPEAIVTADGA DFPMDSSNGNCRGASSERCKCKPIRATQKTYFRNNYNYVIRAKVKEIKTK CHDVTAVVEVKEILKSSLVNIPRDTVNLYTSSGCLCPPLNVNEEYIIMGY EDEERSRLLLVEGSIAEKWKDRLGKKVKRWDMKLRHLGLSKSDSSNSDST QSQKSGRNSNPRQARN |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FRZB重组蛋白的3篇代表性文献的简要概括：
1. **文献名称**: *FRZB, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8*
**作者**: Hoang B. et al.
**摘要**: 该研究首次报道了FRZB作为分泌型Wnt拮抗剂的分子机制，发现其通过结合Wnt-8抑制经典Wnt信号通路，揭示了其在胚胎发育(如Spemann组织中心)中的关键调控作用。
2. **文献名称**: *Functional analysis of FRZB protein and its role in osteoarthritis*
**作者**: Loughlin J. et al.
**摘要**: 研究通过重组FRZB蛋白实验，证明其通过抑制Wnt/β-catenin通路调节软骨细胞分化和基质代谢，提出FRZB基因多态性与骨关节炎易感性相关，为疾病治疗提供潜在靶点。
3. **文献名称**: *Recombinant FRZB enhances bone regeneration by modulating mesenchymal stem cell differentiation*
**作者**: Gaur T. et al.
**摘要**: 利用重组FRZB蛋白处理间充质干细胞，发现其通过平衡Wnt和BMP信号通路促进成骨分化，在小鼠骨缺损模型中显著加速骨愈合，提示其在再生医学中的应用潜力。
注：以上为示例性内容，建议通过PubMed或Google Scholar检索关键词"FRZB recombinant protein"、"Frizzled-related protein"获取最新具体文献。实际引用时需核对作者、标题及摘要准确性。
**Background of FRZB Recombinant Protein**
FRZB (Frizzled-related protein), also known as secreted frizzled-related protein 3 (SFRP3), is a member of the SFRP family, which modulates Wnt signaling—a critical pathway regulating embryonic development, tissue homeostasis, and disease progression. Discovered in the late 1990s, FRZB acts as a soluble antagonist by binding to Wnt ligands or Frizzled receptors, thereby inhibiting Wnt-receptor interactions. Structurally, it contains a cysteine-rich domain (CRD) homologous to the extracellular Wnt-binding region of Frizzled receptors but lacks the transmembrane domain, enabling its secretory nature.
FRZB is prominently expressed in skeletal tissues, including cartilage and bone, where it regulates chondrocyte differentiation and osteogenesis. Studies link FRZB dysfunction to osteoarthritis (OA), as genetic variants or reduced expression correlate with cartilage degradation and joint abnormalities. Its role in cancer is also explored, particularly in tumors driven by Wnt/β-catenin signaling, where FRZB may act as a tumor suppressor by dampening oncogenic Wnt activity.
Recombinant FRZB protein, produced via expression systems like mammalian cells (e.g., HEK293) or *E. coli*, retains the functional CRD for experimental or therapeutic use. It serves as a tool to study Wnt signaling mechanisms, screen inhibitors, or develop biologics targeting Wnt-related pathologies. In regenerative medicine, FRZB recombinant protein has potential in cartilage repair by balancing Wnt-driven catabolic and anabolic processes.
Overall, FRZB recombinant protein bridges basic research and translational applications, offering insights into Wnt biology and therapeutic strategies for diseases like OA and cancer. Its development underscores the importance of fine-tuning Wnt signaling in health and disease.
×
